Scholarlink

Objective <p>To evaluate the efficacy and safety of low-dose rituximab (RTX) strategy in patients with neuromyelitis optica spectrum disorder (NMOSD) over a period exceeding 5 years and to investigate the impact of treatment compliance on clinical outcomes.</p> Methods <p>We conducted a retrospective analysis of 81 NMOSD patients who received low-dose RTX at Tangdu Hospital from January 2014 to December 2019. The treatment protocol involved an induction phase of 100&#xa0;mg weekly for three weeks, followed by maintenance doses of 100&#xa0;mg every six months. Demographic characteristics, the expanded disability status scale (EDSS) scores, annualized relapse rates (ARR), number and date of attacks, and adverse events were collected. The influence of compliance on treatment efficacy was assessed using multivariable Cox regression and propensity score-weighted analysis.</p> Results <p>Over the follow-up period, 32.1% of patients experienced relapses, with the ARR significantly reduced from a median of 1.5 before treatment to 0 after RTX therapy (<i>p</i> &lt; 0.001). EDSS scores improved significantly from a median of 3.5 to 1.5 (<i>p</i> &lt; 0.001). The relapse rate was significantly lower in the good compliance group compared to the poor compliance group (9.5% vs. 56.4%, <i>p</i> &lt; 0.001), and good compliance was associated with a reduced risk of relapse (HR 0.07; 95% CI 0.02–0.25, <i>p</i> &lt; 0.001). A total of 19 patients (23.5%) experienced mild adverse events, with no serious adverse events reported.</p> Conclusion <p>Our findings support the long-term efficacy and safety of low-dose RTX strategy in treating NMOSD, highlighting the crucial role of treatment compliance in achieving favorable clinical outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Long-term efficacy and safety of low-dose rituximab strategy in neuromyelitis optica spectrum disorder: a retrospective cohort study on treatment compliance and clinical outcomes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月23日

查看全文
  • Yao Wang,
  • Cong Zhao,
  • Zonghao Pan,
  • Rui Zhang,
  • Yi Li,
  • Hongzeng Li,
  • Daidi Zhao,
  • Jun Guo

摘要

Objective

To evaluate the efficacy and safety of low-dose rituximab (RTX) strategy in patients with neuromyelitis optica spectrum disorder (NMOSD) over a period exceeding 5 years and to investigate the impact of treatment compliance on clinical outcomes.

Methods

We conducted a retrospective analysis of 81 NMOSD patients who received low-dose RTX at Tangdu Hospital from January 2014 to December 2019. The treatment protocol involved an induction phase of 100 mg weekly for three weeks, followed by maintenance doses of 100 mg every six months. Demographic characteristics, the expanded disability status scale (EDSS) scores, annualized relapse rates (ARR), number and date of attacks, and adverse events were collected. The influence of compliance on treatment efficacy was assessed using multivariable Cox regression and propensity score-weighted analysis.

Results

Over the follow-up period, 32.1% of patients experienced relapses, with the ARR significantly reduced from a median of 1.5 before treatment to 0 after RTX therapy (p < 0.001). EDSS scores improved significantly from a median of 3.5 to 1.5 (p < 0.001). The relapse rate was significantly lower in the good compliance group compared to the poor compliance group (9.5% vs. 56.4%, p < 0.001), and good compliance was associated with a reduced risk of relapse (HR 0.07; 95% CI 0.02–0.25, p < 0.001). A total of 19 patients (23.5%) experienced mild adverse events, with no serious adverse events reported.

Conclusion

Our findings support the long-term efficacy and safety of low-dose RTX strategy in treating NMOSD, highlighting the crucial role of treatment compliance in achieving favorable clinical outcomes.